Article Details
Retrieved on: 2022-10-25 13:59:05
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Acumen Pharmaceuticals believes ACU193 – the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta ...
Article found on: www.biopharma-reporter.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here